India Approves First Dengue Vaccine QDENGA: Key Facts

Context:

Recently, the Drugs Controller General of India (DCGI) granted market authorization to QDENGA (TAK-003), developed by Takeda Biopharmaceuticals. It is India's first approved dengue vaccine. Approved for individuals aged 4-60 years, the vaccine marks a significant step towards strengthening dengue prevention and control in the country.

About QDENGA (TAK-003):

• • • A live-attenuated tetravalent dengue vaccine developed by Takeda Biopharmaceuticals.
    • Provides protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
    • Administered in a two-dose schedule, with the second dose given three months after the first.
    • No pre-vaccination screening is required, and it can be administered regardless of prior dengue infection.

Significance of the Vaccine:

• • • India's first licensed dengue vaccine.
    • Expected to reduce severe dengue, hospitalizations, and deaths.
    • A major milestone for India, which bears nearly one-third of the global dengue burden.
    • Complements existing vector-control and public health measures.

Challenges:

• • • Ensuring affordability and equitable access.
    • Expanding manufacturing capacity and cold-chain infrastructure.
    • Addressing vaccine hesitancy through public awareness.
    • Vaccination alone is insufficient; continued surveillance and vector control remain essential.

Government Initiatives for dengue control:

• • • National Vector Borne Disease Control Programme (NVBDCP) (now the National Centre for Vector Borne Diseases Control – NCVBDC) for disease surveillance, case management, and vector control.
    • Sentinel Surveillance Hospitals (SSHs) and Apex Referral Laboratories (ARLs) provide free dengue diagnosis.
    • Approval of QDENGA and Phase III clinical trials of the indigenous DengiAll vaccine.
    • Development of Wolbachia-infected mosquitoes by the ICMR–Vector Control Research Centre (VCRC) to reduce dengue transmission.
    • Public awareness through National Dengue Day (16 May) and Anti-Dengue Month (July).

About Dengue:

• • • Causative Agent
      • Dengue virus (Family: Flaviviridae).
      • Four serotypes:
      • DENV-1
      • DENV-2
      • DENV-3
      • DENV-4
    • Vector
      • Primarily transmitted by the female Aedes aegypti mosquito.
      • Aedes albopictus can also transmit the virus.
      • The mosquito bites mainly during the daytime.
    • Symptoms
      • High fever
      • Severe headache
      • Joint and muscle pain
      • Skin rash
      • Bleeding manifestations (in severe cases)
    • Severe Forms
      • Dengue Hemorrhagic Fever (DHF)
      • Dengue Shock Syndrome (DSS)

Dengue Situation in India:

• • • India accounts for nearly one-third of the global dengue burden.
    • Reported dengue cases have increased almost 11-fold over the past two decades.
    • The actual number of infections is believed to be much higher due to under-reporting.

About the Drugs Controller General of India (DCGI):

• • • Heads the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health & Family Welfare.
    • Functions under the Drugs and Cosmetics Act, 1940.
    • Key Functions: Approves vaccines and new drugs, regulates clinical trials, sets drug quality standards, and oversees medical devices.
    • Current DCGI: Dr. Rajeev Singh Raghuvanshi.
    • Headquarters: New Delhi.

Conclusion:

The approval of QDENGA marks a significant milestone in India's fight against dengue. However, sustained dengue control requires an integrated approach combining vaccination, disease surveillance, vector control, environmental sanitation, and community participation.